The stock last traded at $28.62 which is just over $25.28, the stock’s 50 day moving average and just a bit higher than the 200 day moving average of $28.08. The 50 day moving average went up by +13.23% and the 200 day average moved up $0.54. (NASDAQ:ACRS) shares saw light trading volume with 211K shares changing hands by the end of trading on Thursday. Overall, volume was down 24.87% under the stocks normal daily volume.
Traders are more bearish on shares of the company if you put credence in the rise in short interest. The stock recorded a rise in short interest from June 15, 2017 to May 31, 2017 of 2.50%. Short shares grew from 2,795,298 to 2,865,161 over that timeframe. With short interest at 2,865,161 and short average daily volume at 390,952, days to cover is 7.3 and the percentage of shorted shares is 0.11% as of May 31.
Here is the rundown on market activity for Aclaris Therapeutics, Inc. (NASDAQ:ACRS). Anand Mehra, Director sold $21,187,500 worth of shares at an average price of $28.25 on Tue the 10th. The Director now owns $43,490,310 of the stock as reported to the SEC. Kamil Ali-jackson, CLO let go of $85,399 worth of shares at an average price of $21.83 on Wed the 26th. That brings Ali-jackson’s holdings to $1,658,141 per an SEC filing yesterday.
Kamil Ali-jackson, CLO disclosed the sale of 1,841 shares. The shares were purchased at an average price of $24.66. The CLO now owns $1,873,100 of the stock according to the SEC filing.
Here are a few other firms who have also updated their positions. As of the end of the quarter Bank Of Montreal /can/ had acquired a total of 6,760 shares growing its stake by 1,793.1%. The value of the total investment in Aclaris Therapeutics, Inc. increased from $11,000 to $194,000 increasing 1,663.6% for the reporting period. As of quarter end Morgan Stanley had sold 9,296 shares trimming its holdings by 88.1%. The value of the investment in Aclaris Therapeutics, Inc. went from $286,000 to $38,000 a change of $248,000 quarter to quarter.
Ecor1 Capital, LLC bolstered its ownership by buying 259,100 shares an increase of 62.6% from 12/31/2016 to 03/31/2017. Ecor1 Capital, LLC now controls 673,100 shares worth $20,072,000. The total value of its holdings increased 78.6%. Tower Research Capital LLC (trc) reduced its holdings by shedding 13 shares a decrease of 13.0% in the quarter. Tower Research Capital LLC (trc) now holds 87 shares with a value of $3,000. The value of the position overall is up by 50.0%.
On June 16, 2017 Cantor Fitzgerald began coverage by announcing an initial rating of “Overweight”. On November 29 analysts at Leerink Swann starting coverage on ACRS with a rating of “Outperform”.
JMP Securities added the stock to its research portfolio with an initial rating of “Market Perform”. On September 19 Jefferies kept the stock rating at “Buy” but moved up the price target to $31.00 from $23.00.
August 12 investment analysts at Jefferies maintained a stock rating of “Buy” and raised the price target from $20.00 to $23.00. Equity analyst Guggenheim Securities released its first research report on the stock giving it an initial rating of “Buy”.
In the market the company is trading up by 1.67 percent from yesterday’s close. As of the last earnings report the EPS was $-2.08 and is projected to be $-3.22 for the current year with 26,733,000 shares presently outstanding. Next quarter’s EPS is forecasted to be $-0.85 and the next full year EPS is anticipated to be $-3.21.
Aclaris Therapeutics, Inc., launched on July 13, 2012, is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications..